Tambov

Researchers are evaluating the effectiveness, safety, how the body processes, and immune response to BCD-236 combined with chemotherapy in women with relapsed or metastatic triple negative breast cancer TNBC who have received previous treatments. This is a Phase 2 study that compares BCD-236 plus chemotherapy versus chemotherapy alone in patients whose cancer has returned or progressed after earlier therapies. Participants will be randomly assigned to one of two groups one receiving BCD-236 by intravenous infusion plus chemotherapy chosen by the investigator, and the other receiving chemotherapy alone. Treatment continues until the cancer worsens, side effects become intolerable, or the study ends. During the study, participants will undergo regular assessments including tumor measurements and health evaluations to monitor response and side effects. The main outcome measured is the overall response rate at 24 weeks, with secondary outcomes including progression-free survival, overall survival, disease control rate, time to response, and duration of response assessed at various times up to 102 weeks. Participants will be monitored closely throughout their treatment and follow-up periods.

This research aims to evaluate treatments for reticular leg veins, which are mainly a cosmetic concern. The study compares three approaches a 1064 nm long-pulsed NdYAG laser alone, a combination of this laser with sclerotherapy, and sclerotherapy alone. The goal is to assess the effectiveness and side effects of these methods to determine the best treatment option, as sclerotherapy can cause persistent skin discoloration that affects patient satisfaction. Participants are randomly assigned to one of three groups. One group receives laser treatment with specific laser settings, another receives the laser combined with a foam polidocanol injection, and the third group receives sclerotherapy using foam polidocanol alone. Photos of the affected area are taken before treatment, and ultrasound measures the maximum vein diameter. Each treatment aims to eliminate the reticular veins. During the study, participants will have their treated veins monitored with photos and ultrasound. Researchers will evaluate vein disappearance at six months, pain during the procedure, patient satisfaction, and skin discoloration. The trial includes safety monitoring, and the total duration for outcome measurement is six months after treatment.

Researchers are evaluating the safety and effectiveness of endovenous thermal ablation treatments for large saphenous veins larger than 15 mm in diameter, which cause varicose veins in the lower limbs. This study focuses on comparing two methods one using a standard laser fiber and another using a laser fiber with vacuum evacuation to reduce complications and improve recovery. The goal is to better understand which approach is safer and more effective in treating symptomatic vein reflux. Participants receive endovenous laser ablation using either the ELVeS Radial 2ring fiber or the ELVeS Radial 2ring Pro fiber. The Pro fiber is connected to a vacuum suction during the procedure to remove remaining blood from the vein and potentially lower risks like heat-induced thrombosis. Before treatment, patients are examined with ultrasound to measure vein diameters, and the energy used for laser ablation is calculated based on these measurements. Compression stockings are worn after the procedure to support recovery. During the study, participants will be monitored at multiple time points one day, two weeks, one month, three months, and six months after treatment. Researchers will assess vein occlusion, pain levels, clinical status, severity of chronic venous disease, quality of life, and any side effects like hyperpigmentation or adverse events. Histological analysis of the treated veins will also be performed at selected times. This follow-up helps track how well each treatment works and the participants overall health during recovery.